Updated:
Aethlon Medical Inc.
Aethlon Medical Inc. is a publicly traded medical device firm developing hemopurification technology for cancer and infectious disease, not a family...
Aethlon Medical Inc.
Aethlon Medical Inc. is a publicly listed company on the OTC Markets under the ticker AEMD. It operates in the medical device sector, specializing in the development of the Hemopurifier, a therapeutic tool designed to remove viruses and toxins from blood. The firm is classified as an asset manager in the Altss taxonomy based on its corporate structure, but its primary activity is product development rather than investment management. Aethlon Medical's strategy centers on advancing its Hemopurifier through regulatory approvals and clinical trials. The device targets oncology applications by filtering exosomes that promote tumor growth, and infectious disease applications by capturing viruses such as HIV and hepatitis. The firm has pursued partnerships and grants, including funding from the National Institutes of Health (per the firm's SEC filings). Geographic operations are US-based, with clinical activities in India and other regions. The firm maintains a small team and reports financials through public filings. As a publicly traded entity, its capital structure includes equity financings and public offerings rather than family office-style deployment. Aethlon Medical does not disclose AUM or deployment figures in the context of asset management. Aethlon Medical's structural differentiator is its therapeutic hemofiltration platform, which is distinct from typical family office or asset manager mandates. The firm's model is corporate R&D combined with public equity, driven by scientific milestones rather than investment returns. Succession and governance are determined by public company board structures and SEC regulation.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
Who runs investment decisions at Aethlon Medical Inc.?
Aethlon Medical Inc. is a publicly traded company (OTC: AEMD) led by its CEO and board of directors. As of public filings, Dr. Charles J. Fisher Jr. serves as CEO. The firm does not have investment decision-makers in the family office sense; capital allocation is managed by the executive team and board under SEC oversight (per the firm's proxy statements).
How does Aethlon Medical source proprietary deal flow?
Aethlon Medical does not seek deal flow for investment. It is a medical device company that sources technology partnerships and clinical collaborations rather than investment opportunities. Its proprietary position comes from its Hemopurifier intellectual property (per the firm's SEC filings).
Is Aethlon Medical structured as a single family office or does it operate more like a venture firm?
Aethlon Medical is structured as a publicly traded operating company, not a family office or venture firm. It reports under SEC regulations and has a market capitalization in the tens of millions of dollars range as of recent filings (per public financial data).
What investment stages does Aethlon Medical typically target?
Aethlon Medical does not target investment stages. The firm's activities are centered on product development and clinical-stage trials for its Hemopurifier. It is a non-investing entity.
Which sectors does Aethlon Medical explicitly avoid?
Aethlon Medical focuses exclusively on medical devices and therapeutic filtration. It does not engage in financial investments, real estate, or other sectors typical of family offices. Its sector avoidance is a byproduct of its narrow business model.
How is Aethlon Medical related to other entities?
Aethlon Medical Inc. is a standalone publicly traded corporation. It has no known affiliation with any family office, wealth management entity, or investment firm. No parent or related investment vehicles are disclosed in public records.
Where does the underlying wealth come from?
Aethlon Medical does not manage wealth. Its capital is raised through public equity offerings and grants, not family or institutional wealth. The firm's balance sheet is funded by shareholder investments (per SEC filings).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: